Amuvatinib hydrochloride is primarily used in the field of oncology as a targeted therapy for certain types of cancer. It functions as a multi-kinase inhibitor, which means it can block several enzymes involved in cancer cell growth and proliferation. This makes it particularly effective in treating cancers that are driven by specific genetic mutations or overactive signaling pathways.

One of its key applications is in the treatment of small cell lung cancer (SCLC) and other solid tumors. It has shown potential in inhibiting the activity of c-KIT and PDGFRα, which are often implicated in tumor growth and metastasis. Additionally, amuvatinib hydrochloride is being investigated for its role in overcoming resistance to other cancer therapies, such as tyrosine kinase inhibitors, making it a valuable component in combination treatment regimens.

Research is also exploring its efficacy in targeting cancer stem cells, which are often responsible for tumor recurrence and resistance to conventional treatments. By targeting these cells, amuvatinib hydrochloride may help improve long-term outcomes for patients with aggressive or refractory cancers.

Overall, its ability to interfere with multiple signaling pathways and its potential to enhance the effectiveness of other therapies make it a promising candidate in the ongoing fight against cancer.